0K
BIO

Evolving HumanLongevity

Leveraging synthetic biology and machine learning to develop adaptive gene therapies that enhance both lifespan and healthspan. We're redefining the boundaries of human potential.

SCROLL TO EXPLORE↓

Evolution is the only approach proven to work

Human aging is not an immutable ceiling—it's a challenge that nature has already overcome. By replicating the environments that shaped immortal organisms, we can harness the same evolutionary principles to unlock new pathways to longevity.

Our Technology

We combine advanced machine learning with the Design-Build-Test-Learn (DBTL) cycle to drive continuous genome evolution. Our process uses multiple in silico heuristics to guide in vitro experiments, where both the computational and experimental models iteratively improve one another. This modular platform is built for high throughput, rapid cycle times, and parallelization, enabling efficient scaling of experiments.

LEARN MORE ABOUT OUR TECHNOLOGY→

Research Roadmap

Phase 1

Cell Immortalization

Demonstrate 20-30% lifespan extension in HDFs using our AI-guided CRISPR-X continuous evolution platform, with comprehensive safety validation.

Phase 2

Automated Scale-up

Transfer validated cell lines to automated biofoundry systems (Ginkgo Bioworks, Paris BioFoundry) for high-throughput experimentation and optimization.

Phase 3

Organoid Development

Scale up to human organoids to validate longevity enhancements in complex tissue environments and study cell-cell interactions.

Phase 4

Organ-on-Chip Validation

Utilize human-on-a-chip and organ-on-chip systems to assess systemic effects and validate safety in interconnected tissue models.

Phase 5

Advanced In Vivo Models

Progress to humanized mouse models and patient-derived xenografts for comprehensive validation of safety and efficacy in living systems.

MEET THE TEAM→

Common Questions

GET IN TOUCH→